J&J's exit from the coronary angioplasty market was a sign of the end of an era. Without a product at the high end of innovation, it was left with a basic product that in the interim had become commoditized.

More than a decade ago, venture capitalists identified neurostimulation as a fertile new field for investment, but efforts to date have produced more disappointments than results. The losing streak appears to be over: the FDA recently cleared Neuronetics to begin selling its NeuroStar TMS system for treatment-resistant depression. Meanwhile, Northstar Neuroscience has received FDA approval for the second study of its Renova cortical stimulation device for treating major depressive disorder.

Heart Technology is one of the great success stories in medical devices over the past 20 years. But you'd never have predicted that given the company's early experiences. In Vivo interviews the company's founder, David Auth.

China's medical device market is now the world's third largest, behind only the US and Japan, and some predict that China may well surpass Japan within a decade. Delving beneath the surface of China's medtech industry reveals a complex and steadily maturing dynamic, and a market that may be considerably larger than estimates suggest.